Adverum Biotechnologies logo
Adverum Biotechnologies
ADVM | NASDAQ
Chart Builder DCF Calculator
$4.36
$0.00 (0.00%)
At close: Dec 9, 2025, 4:00 PM ET

Adverum Biotechnologies Company Profile

Company profile explained

Company Profile

Adverum Biotechnologies, Inc. is a clinical-phase biotechnology firm primarily engaged in discovering and advancing gene therapies. The company's mission is to create innovative treatments for various eye-related conditions and uncommon illnesses. Its flagship experimental gene therapy, ADVM-022, is a potential therapy administered through a single injection into the vitreous humor of the eye. This treatment is being developed for individuals afflicted with persistent retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies maintains licensing and collaborative partnerships with institutions such as the University of California and Cornell University, as well as companies like GenSight, Lexeo, and Virovek. Established in 2006, the organization was initially named Avalanche Biotechnologies, Inc. before rebranding to Adverum Biotechnologies, Inc. in May 2016. Its headquarters are situated in Redwood City, California.

Key Executives

Name Position
Laurent Fischer President, Chief Executive Officer & Director
Dena House Chief People Officer
Kishor Peter Soparkar Chief Operating Officer
Linda Rubinstein Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer
R. Andrew Ramelmeier Chief Technology Officer
Aneta Ferguson General Counsel
Carla Fiankan Senior Vice President of Regulatory Affairs
Rabia Gurses Ozden Chief Medical Officer
Romuald Corbau Chief Scientific Officer
Setareh Seyedkazemi Chief Development Officer

Latest SEC Filings

Date Type Title
Dec 19, 2025 15-12G Filing
Dec 11, 2025 EFFECT Filing
Dec 11, 2025 EFFECT Filing
Dec 11, 2025 EFFECT Filing
Dec 10, 2025 4 Filing
Dec 10, 2025 4 Filing
Dec 10, 2025 4 Filing
Dec 10, 2025 4 Filing
Dec 10, 2025 4 Filing
Dec 10, 2025 4 Filing
View All SEC Filings ➞
Adverum Biotechnologies
Adverum Biotechnologies logo
Country United States
IPO Date Jul 31, 2014
Industry Biotechnology
Sector Healthcare
Employees 155
CEO Laurent Fischer

Contact Details

800 Saginaw Drive Redwood City, California 94063 United States

Stock Details

Ticker Symbol ADVM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001501756
CUSIP Number 00773U207
ISIN Number US00773U2078
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.